Toenail Fungus (Onychomycosis): Causes, Risks & Prevalence
Onychomycosis is the condition quietly governing this entire product category: its biology sets the timelines, its persistence explains the frustration, and its prevalence explains the market. Here is the condition as authoritative sources describe it — no product involved.
What it is, precisely
Onychomycosis is fungal infection of the nail unit — most often dermatophytes, with Trichophyton rubrum the usual headline name, joined by yeasts and non-dermatophyte molds in a minority of cases. The classic presentation (distal lateral subungual type) begins at the nail's far edge: discoloration, then thickening, brittleness and debris under the plate as the organism works inward.
How common is it?
Epidemiologic literature and reference texts (StatPearls among them) place onychomycosis around 10% of the general population, rising steeply with age — into the double-digit tens of percent among older adults — making it the most common nail disease in adults. It is a near-universal human experience to know someone treating it, which is the demand side of every nail-product market.
Who gets it: the risk profile
- Age — slower nail growth and cumulative exposure.
- Athlete's foot — the skin reservoir that seeds nails; treating foot skin matters as much as treating nails.
- Occlusive footwear and moist environments — communal showers, pools, sweaty boots: fungus is a moisture-loving organism.
- Diabetes and circulatory disease — both risk and complication, and the reason diabetic foot care is clinician-supervised.
- Immunosuppression and, modestly, genetics and trauma — a stubbed nail is an open door.
Why it is so persistent
Three biology facts explain the frustration everyone in this category feels. First, the nail plate is armor: dense keratin evolved to keep organisms and chemicals out, which protects the fungus as much as you. Second, nails grow slowly — toenails 1–2 mm per month, full replacement over 12–18 months — so even successful treatment shows as months of waiting for damaged nail to exit. Third, reinfection is routine: the same shoes, socks and shower floors that hosted the original infection happily host the next one, which is why hygiene work appears in every serious protocol, including our foot hygiene article.
The public-health angle the vendor cites
Antifungal resistance — the concern behind the vendor's CDC-linked opening argument — is a documented public-health topic: incomplete, abandoned courses select for tougher organisms. The honest read, as our how it works page states, is that this argues for consistency and completion in whatever route you choose, not for any specific product.
Where treatments sit, briefly
Confirmed disease has an evidence ladder: oral terbinafine at the strong end, prescription topicals (ciclopirox, efinaconazole, tavaborole) in the middle, OTC and cosmetic topicals — including oil blends like Kerassentials — at the supportive/mild end, with hygiene underpinning all of it. The topical vs oral explainer unpacks the ladder; the alternatives framework turns it into a decision.
The paragraph that matters for buyers
Understanding onychomycosis converts product marketing from magic into mechanics: any plausible topical is fighting armor, slow growth and reinfection, which is why realistic expectations live in months, why terrain and hygiene matter, and why diagnosed moderate-to-severe disease belongs with a clinician. A buyer who holds that map cannot be sold a miracle — which is, as ever, the point of this library.
References
- StatPearls. Onychomycosis. NCBI Bookshelf. (Epidemiology, pathogens, risk factors.)
- U.S. CDC antifungal resistance background materials.
- Adams C, et al. Environmental and genetic factors on the development of onychomycosis. Journal of Fungi. 2015;1(2):211-6.